Literature DB >> 7676165

Frequency of EEG arousals from nocturnal sleep in normal subjects.

R Mathur1, N J Douglas.   

Abstract

Brief arousals are clinically important and increasingly scored during polysomnography. However, the frequency of arousals during routine polysomnography in the normal population is unknown. We performed overnight polysomnography in the 55 of 59 control subjects from a family practice list who were approached and agreed to undergo polysomnography. Awakenings were scored according to the criteria of Rechtschaffen and Kales and briefer arousals according to three different criteria, including the American Sleep Disorders Association (ASDA) definition. There was a mean of 4 [95% confidence interval (CI), 1-15) Rechtschaffen and Kales awakenings per hour, whereas the ASDA definition gave 21 (95% CI, 7-56) per hour slept. Arousal frequencies increased significantly (p < 0.001) with age in our subjects, who ranged from the late teens to early 70s. The high upper limit of the frequency of brief arousals was not altered by exclusion of patients who snored or had witnessed apneas or daytime sleepiness. It is important that those scoring arousals on routine polysomnography recognize that high arousal frequencies occur in the normal population on 1-night polysomnography.

Entities:  

Mesh:

Year:  1995        PMID: 7676165     DOI: 10.1093/sleep/18.5.330

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  27 in total

1.  Treatment of central sleep apnoea in congestive heart failure with nasal ventilation.

Authors:  G N Willson; I Wilcox; A J Piper; W E Flynn; R R Grunstein; C E Sullivan
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 2.  Sleep apnoea and hypertension: proof at last?

Authors:  J R Stradling; J C Pepperell; R J Davies
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 3.  Sleep and cardiovascular regulation.

Authors:  John Trinder; Joanna Waloszek; Michael J Woods; Amy S Jordan
Journal:  Pflugers Arch       Date:  2011-10-26       Impact factor: 3.657

4.  Can an inert sleeping pill affect sleep? Effects on polysomnographic, behavioral and subjective measures.

Authors:  Fabiana Fratello; Giuseppe Curcio; Michele Ferrara; Cristina Marzano; Alessandro Couyoumdjian; Giovanna Petrillo; Mario Bertini; Luigi De Gennaro
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 5.  Adult obstructive sleep apnea: pathophysiology and diagnosis.

Authors:  Susheel P Patil; Hartmut Schneider; Alan R Schwartz; Philip L Smith
Journal:  Chest       Date:  2007-07       Impact factor: 9.410

6.  Impact of microarousal associated with increased negative esophageal pressure in sleep-disordered breathing.

Authors:  Mayo Sukegawa; Akiko Noda; Yoshinari Yasuda; Seiichi Nakata; Tatsuki Sugiura; Seiko Miyata; Kumiko Honda; Yoshinori Hasegawa; Tsutomu Nakashima; Yasuo Koike
Journal:  Sleep Breath       Date:  2009-05-15       Impact factor: 2.816

Review 7.  Polysomnographic effects of hypnotic drugs. A review.

Authors:  L Parrino; M G Terzano
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

8.  Sleep and Respiration in 100 Healthy Caucasian Sleepers--A Polysomnographic Study According to American Academy of Sleep Medicine Standards.

Authors:  Thomas Mitterling; Birgit Högl; Suzana Veiga Schönwald; Heinz Hackner; David Gabelia; Marlene Biermayr; Birgit Frauscher
Journal:  Sleep       Date:  2015-06-01       Impact factor: 5.849

9.  Improvement of Parasomnias After Treatment of Restless Leg Syndrome/ Periodic Limb Movement Disorder in Children.

Authors:  Neepa Gurbani; Thomas J Dye; Kyle Dougherty; Sejal Jain; Paul S Horn; Narong Simakajornboon
Journal:  J Clin Sleep Med       Date:  2019-05-15       Impact factor: 4.062

10.  Clinical presentation of obstructive sleep apnea in patients with end-stage renal disease.

Authors:  Jaime M Beecroft; Andreas Pierratos; Patrick J Hanly
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.